Bee Venom Therapy for Lyme Disease
Bee-venom therapy is not an evidence-based treatment for Lyme disease. Current Lyme disease guidelines recommend antibiotic therapy based on the clinical manifestation, while bee-venom therapy is not listed as a recommended treatment. [1][2]
Recommended Evidence-Based Treatment for Lyme Disease
For early localized Lyme disease with erythema migrans, recommended treatment is oral doxycycline, amoxicillin, or cefuroxime axetil. [1]
For neurologic Lyme disease and other specific manifestations, guideline-recommended antibiotic regimens vary by manifestation. [2]
Evidence for Bee Venom Therapy
Available evidence for bee-venom therapy is primarily preclinical. [3][4]
In vitro studies have demonstrated antimicrobial activity of whole bee venom (Apis mellifera venom) and melittin against Borrelia burgdorferi, including effects on forms described as biofilm-associated or persistent in laboratory assays. [3]
In vitro studies have shown that melittin can rapidly inhibit B. burgdorferi motility at low concentrations in laboratory culture systems. [4]
No randomized controlled trials or other high-quality human clinical trials demonstrating clinical benefit of bee-venom therapy for Lyme disease were identified in the available PubMed-indexed evidence retrieved for this question. [3][4]
Clinical Benefit vs Laboratory Activity
Preclinical antimicrobial activity against Borrelia burgdorferi does not establish clinical efficacy in humans. [3][4]
Guideline-recommended Lyme disease treatments are supported by clinical evidence showing cure rates and clinical outcomes for specific manifestations. [1][2]
Safety and Risk Considerations
Bee-venom therapy carries risk of clinically significant hypersensitivity reactions in susceptible individuals, which can limit its use as a non-guideline therapy. [5]
Treatment Implications
For suspected or confirmed Lyme disease, guideline-directed antibiotic therapy is recommended rather than bee-venom therapy. [1][2]
Sources to Consult for Manifestation-Specific Therapy
Manifestation-specific antibiotic regimens are provided by CDC and the IDSA/AAN/ACR Lyme disease guidelines. [1][2]
Inquiries about nonstandard therapies are best directed to clinicians familiar with Lyme disease management due to the absence of guideline support for bee-venom therapy. [1][2]